Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13548041 | 0.86 | TSHR (0.37) | TSHRSMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL13548044 | 0.85 | KMT2A (0.34) | SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL5490079 | 0.82 | L3MBTL1 (0.39) | SMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL13548001 | 0.80 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL3598240 | 0.79 | MEN1 (0.34) | SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL3603326 | 0.79 | MEN1 (0.34) | SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL12029957 | 0.78 | FFAR4 (0.38) | TSHRSMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL13548008 | 0.78 | CYP19A1 (0.39) | TSHRSMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL16511761 | 0.75 | POLB (0.46) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5485798 | 0.75 | NLRP3 (0.35) | SMN1; SMN2ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022527-A1 | BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES | DHFR, RORA, CYP2A6 | TSHR 1548/4885HSD17B10 330/4885SMN1; SMN2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.